Novo Nordisk A/S shares plunged after the company shocked investors by forecasting a steep decline in sales, evidence of an intensifying price war in obesity drugs.Sales will fall by as much as 13% this year, the company said Tuesday. Pressure from lower prices for its blockbuster weight-loss drugs, in part due to the US government's push to cut prices, will contribute to the decline. The shares fell as much as 20% in early Copenhagen trading, the biggest intraday decline since July, more than wiping out the previous gains for this year. Sam Fazeli, Director of Research at Bloomberg Intelligence joins Stephen Carroll and Caroline Hepker to discuss. (Source: Bloomberg)